Literature DB >> 14593554

Cardiovascular health in women with polycystic ovary syndrome.

Sara Sukalich1, David Guzick.   

Abstract

Polycystic ovary syndrome (PCOS) is arguably the most common endocrinopathy among women of reproductive age. Women with PCOS have clinical characteristics that are associated with insulin resistance, vascular dysfunction, hypertension, and dyslipidemia. Although definitive data for increased cardiovascular events in women with PCOS are lacking, case-control studies have documented an increased risk of preclinical cardiovascular disease. Thus, PCOS should be viewed as a chronic condition that may ultimately have long-term health impacts and patients should be counseled to reduce cardiovascular risk factors through weight control, exercise, and/or pharmacologic treatments.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593554     DOI: 10.1055/s-2003-43309

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  3 in total

1.  Metabolomics reveals impaired maturation of HDL particles in adolescents with hyperinsulinaemic androgen excess.

Authors:  Sara Samino; Maria Vinaixa; Marta Díaz; Antoni Beltran; Miguel A Rodríguez; Roger Mallol; Mercedes Heras; Anna Cabre; Lorena Garcia; Nuria Canela; Francis de Zegher; Xavier Correig; Lourdes Ibáñez; Oscar Yanes
Journal:  Sci Rep       Date:  2015-06-23       Impact factor: 4.379

Review 2.  Obstetric complications in women with IVF conceived pregnancies and polycystic ovarian syndrome.

Authors:  Sunita R Tandulwadkar; Pooja A Lodha; Nirzari T Mangeshikar
Journal:  J Hum Reprod Sci       Date:  2014-01

3.  Pregnancy Outcomes of Women With Polycystic Ovary Syndrome for the First In Vitro Fertilization Treatment: A Retrospective Cohort Study With 7678 Patients.

Authors:  Su Liu; Meilan Mo; Shan Xiao; Longfei Li; Xiuyu Hu; Ling Hong; Linlin Wang; Ruochun Lian; Chunyu Huang; Yong Zeng; Lianghui Diao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-25       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.